• Customer Login
  • Search
KindredBio
  • About
    • Background
    • KindredBio Leadership
    • Board of Directors
  • Products
    • Mirataz® (mirtazapine transdermal ointment)
      • Mirataz home
      • About Feline Weight Loss
      • Mechanism of Action
      • Efficacy
      • Safety
      • Dosing and Administration
      • Resources
      • Mirataz News
      • For Cat Owners
      • Frequently Asked Questions
    • Zimeta™ (dipyrone injection)
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Pipeline
    • Feline Pipeline
    • Canine Pipeline
    • Equine Pipeline
    • Clinical Trials
  • Education
    • Continuing Education
    • KINections
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Pipeline
      • epoCat™ (feline recombinant erythropoietin)
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Menu
News
You are here: Home / News / Future Events / No Events Currently Scheduled

No Events Currently Scheduled

February 12, 2013/in Future Events /by Russell Radefeld
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/2017/09/KindredBioHeader2017.png 0 0 Russell Radefeld /wp-content/uploads/2017/09/KindredBioHeader2017.png Russell Radefeld2013-02-12 22:25:522016-02-12 22:27:50No Events Currently Scheduled

KindredBio News

  • Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs
  • Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results
  • Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results
  • Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results
  • Event: Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit

News Archives

  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • August 2015
  • May 2015
  • March 2015
  • December 2014
  • November 2014
  • August 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • December 2013
  • August 2013
  • July 2013
  • March 2013
  • February 2013
  • January 2013

News

  • Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in DogsMarch 24, 2020 - 8:33 am
  • Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial ResultsMarch 16, 2020 - 4:03 pm
  • Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial ResultsMarch 3, 2020 - 4:04 pm

Events

  • Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial ResultsMarch 3, 2020 - 4:05 pm
  • Event: Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health SummitFebruary 18, 2020 - 8:38 am
  • Event: Kindred Biosciences to Present at Stifel Healthcare ConferenceNovember 14, 2019 - 4:11 pm
$3.98 Stock is No Change 0.00 (0.00%)
KIN (Common Stock)
Previous Close Volume
$3.98 392,401
Intraday High Intraday Low
$4.33 $3.90
52 Week High 52 Week Low
$11.93 $3.10
Exchange: NASDAQ CM

KindredBio proudly supports
Rabies Free Africa

Contact Us | Careers | Privacy Policy | Website Terms of Use | Forward Looking Statements
© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010
KindredBio Announces Filing of an Investigational New Animal Drug Application... KindredBio Announces the Filing of an INAD for Laminitis in Horses
Scroll to top